Return to the Home Page

Go to this topic's parent

Go to the previous topic in the book structure

Go to the next topic in the book structure

Search the site

September 2016

Central Nervous System


  • zopiclone – added a note about a usual starting dose of 3.75 mg
  • flumazenil (benzodiazepine antagonist) – added a dose
  • clonazepam – added a minimum dosing interval

Antipsychotic Drugs

  • long acting/modified release injections are available for some antipsychotics and must not be confused with the other injectable forms – added a note
  • haloperidol – added a QT prolongation note
  • clozapine – added a note about prescribing a regular laxative and a note about TDM

Antidepressant drugs

  • fluoxetine – changed upper dose in range from 80 mg to 60 mg/day
  • venlafaxine – changed upper dose in range from 150 mg to 225 mg/day
  • mirtazapine – removed PHARMAC restriction comment as no longer restricted.

Central Nervous System Stimulants

  • methylphenidate – added trade names to minimise confusion


  • lacosamide – added
  • levetiracetam – increased upper limit of iv dose

Dopaminergic Drugs used in Parkinsonism

  • different formulations of levodopa combinations have different durations of action – added a note
  • levodopa combinations – changed dose information to initial doses
  • lisuride – removed as delisted by PHARMAC

Drugs used in Neuromuscular Disorders

  • pyridostigmine – added an upper dose comment
  • dantrolene – added a malignant hyperthermia iv dose



  • cefotaxime – deleted
  • cefepime – deleted

Other Beta-lactams – carbapenems

  • imipenem + cilastatin – deleted
  • ertapenem – added

Other antimicrobials

  • fusidate sodium – deleted
  • nitrofurantoin – adjusted the use in renal dysfunction comment
  • rifampicin – added
  • vancomycin – changed lower dose in dose range


  • norfloxacin – deleted

Antifungal Drugs

  • amphotericin B (liposomal) – deleted
  • itraconazole – adjusted the absorption comment

Antiviral Drugs

  • Some antivirals sound very similar – added a note
  • valaciclovir – added
  • Hepatitis treatment – added note for hepatitis B and to consult about Hepatitis C drugs

Endocrine System

  • warfarin – clarified different brands and added an alert


  • Mixed insulins – added note about mixed insulins not being equivalent

Thyroid and Antithyroid Drugs

  • levothyroxine – removed the note about different brands not being interchangeable

Male Sex Hormones and Antagonists

  • cyproterone – increased upper dose in range

Drugs affecting Bone Metabolism

  • zoledronic acid – added clarification around indication for each formulation

Pharmacology Guidelines

Routes of Administration

  • Intravenous (IV) – added clarification around single vs. multiple lumens

Drug-Food Interactions

  • reviewed

Therapeutic Drug Monitoring (TDM)

  • Table – added all included in TDM profiles

Drug-Drug Interactions

  • Drugs commonly involved in interactions – removed

Drug Metabolism and Transport

  • CYP enzymes – throughout re-organised substrates, split inhibitors into strong and moderate (with definitions) and included only significant inducers (with definition)
  • transporters – added comment about the effect of inhibitors and inducers

Return to the Home Page

Topic Code: 308672